Haoyang Yu
Research Subjects
Haoyang Yu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Caixia Wang
Chinese Academy of Quality and Inspection & Testing , Beijing 100176
4 shared publications - Chunyan Feng
Chinese Academy of Quality and Inspection & Testing , Beijing 100176
3 shared publications - Haoxuan Li
Chinese Academy of Quality and Inspection & Testing Animal Inspection and Quarantine Institute Beijing 100176
3 shared publications - Shaoqiang Wu
Chinese Academy of Inspection and Quarantine, Beijing, China
3 shared publications - Xiangmei Lin
Institute of Animal Inspection and Quarantine, Chinese Academy of Inspection and Quarantine, Beijing, China
3 shared publications - Songyin Qiu
Chinese Academy of Quality and Inspection & Testing Animal Inspection and Quarantine Institute Beijing 100176
2 shared publications
Latest Publications
- 18 February 2026
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
A Sensitive and Broad-Spectrum Real-Time Reverse Transcription Quantitative PCR Assay for the Detection of Bovine Coronavirus
Background: Bovine coronavirus (BCoV) is an economically significant pathogen that causes respiratory and enteric infections in cattle and wild ruminants. Although multiple diagnostic methods are available, there is still an urgent need for a sensitive real-time reverse transcription quantitative PCR (RT-qPCR) assay capable of detecting continuously emerging novel strains of BCoV. Objective: This study aimed to develop a sensitive and broad-spectrum RT-qPCR assay for the efficient detection of BCoV. Methods: Following optimization and comparison of two primer-probe sets targeting the M gene, an RT-qPCR assay was established. Using Decaro’s method as a reference, gradient dilutions of transcribed RNA solutions and BCoV-derived cDNA were prepared to test sensitivity, repeatability, and reproducibility. Additionally, four other bovine viruses were used to evaluate specificity. Finally, the diagnostic sensitivity and specificity of both assays were analyzed using 46 field samples. Results: A sensitive and broad-spectrum RT-qPCR assay was developed in this study. Its analytical sensitivity was 10 copies/μL with transcribed RNA as the template, comparable to that of Decaro’s method. While the cDNA of an emerging Chinese viral isolate was used as the template, the analytical sensitivity was one order of magnitude higher than that of Decaro’s method. Reproducibility testing revealed intra-assay coefficients of variation (CV) ranging from 1.75 to 3.56%, and inter-assay CV values between 3.13 and 4.91%. When evaluating the diagnostic sensitivity and specificity with 46 field samples, our assay exhibited higher diagnostic sensitivity compared to Decaro’s method, a difference explained by two mutations within the primer and probe regions of Decaro’s method. Conclusion: A highly sensitive and broad-spectrum RT-qPCR assay was successfully developed for the detection of BCoV, especially for the detection of emerging novel strains. Highlights: The RT-qPCR assay developed in this study exhibited high sensitivity, particularly in detecting BCoV field strains and newly emerging variants circulating in recent years.
- 18 February 2026
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
A Sensitive and Broad-Spectrum Real-Time Reverse Transcription Quantitative PCR Assay for the Detection of Bovine Coronavirus
Background: Bovine coronavirus (BCoV) is an economically significant pathogen that causes respiratory and enteric infections in cattle and wild ruminants. Although multiple diagnostic methods are available, there is still an urgent need for a sensitive real-time reverse transcription quantitative PCR (RT-qPCR) assay capable of detecting continuously emerging novel strains of BCoV. Objective: This study aimed to develop a sensitive and broad-spectrum RT-qPCR assay for the efficient detection of BCoV. Methods: Following optimization and comparison of two primer-probe sets targeting the M gene, an RT-qPCR assay was established. Using Decaro’s method as a reference, gradient dilutions of transcribed RNA solutions and BCoV-derived cDNA were prepared to test sensitivity, repeatability, and reproducibility. Additionally, four other bovine viruses were used to evaluate specificity. Finally, the diagnostic sensitivity and specificity of both assays were analyzed using 46 field samples. Results: A sensitive and broad-spectrum RT-qPCR assay was developed in this study. Its analytical sensitivity was 10 copies/μL with transcribed RNA as the template, comparable to that of Decaro’s method. While the cDNA of an emerging Chinese viral isolate was used as the template, the analytical sensitivity was one order of magnitude higher than that of Decaro’s method. Reproducibility testing revealed intra-assay coefficients of variation (CV) ranging from 1.75 to 3.56%, and inter-assay CV values between 3.13 and 4.91%. When evaluating the diagnostic sensitivity and specificity with 46 field samples, our assay exhibited higher diagnostic sensitivity compared to Decaro’s method, a difference explained by two mutations within the primer and probe regions of Decaro’s method. Conclusion: A highly sensitive and broad-spectrum RT-qPCR assay was successfully developed for the detection of BCoV, especially for the detection of emerging novel strains. Highlights: The RT-qPCR assay developed in this study exhibited high sensitivity, particularly in detecting BCoV field strains and newly emerging variants circulating in recent years.
- 29 January 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 805, 153381
Characterization of two monoclonal antibodies that capture and neutralize LSDV via distinct novel epitopes
- 29 January 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 805, 153381
Characterization of two monoclonal antibodies that capture and neutralize LSDV via distinct novel epitopes
- 28 August 2025
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 109 (2) , 252-260
Development of Blocking ELISA Kit Based on Recombinant Monoclonal Antibody for the Serological Diagnosis of Peste Des Petits Ruminants Virus
Background: Peste des petits ruminants (PPR) is a highly contagious and economically devastating disease affecting sheep and goats. The performance and cost of serological diagnostic kits remain a major challenge for PPR eradication. Objective: The nucleocapsid (N) protein of PPR virus and its monoclonal antibody (mAb) were engineered for development of a blocking ELISA. Methods: The N protein was truncated and expressed by the eukaryotic expression system. The mAb 65A8 was recovered, followed by sequencing and cloning of its variable regions into expression vector. The recombinant mAb was expressed in 293F cells. Key characteristics of the recombinant mAb were evaluated. A blocking ELISA was developed and validated. Comparison between the blocking ELISA and a commercial blocking ELISA kit was performed. Results: The truncated N protein exhibited a higher yield compared to the full-length N protein. Recombinant mAb 65A8 demonstrated the same blocking efficacy as that of ascites-derived mAb. The yield of recombinant mAb reached 5.3 mg/100 mL. The affinity constant of recombinant mAb 65A8 was comparable to that of the ascites-derived 65A8 (3.48 × 109 L/mol versus 6.76 × 109 L/mol). Based on the truncated N and recombinant mAb, a blocking ELISA was established. The detection limit of blocking ELISA was 1:128 and 1:32 based on strong positive serum and weak positive serum, respectively. Inter- and intra-assay coefficients of variation were <10%, indicating robust reproducibility. The blocking ELISA kit showed high coincidence with the commercial ELISA kit recommended by the World Organization for Animal Health reference laboratory. Conclusions: This study successfully developed a reliable and cost-effective blocking ELISA by protein engineering of the antigen and mAb. Highlights: The mAb of PPR Virus was recombinantly expressed in 239F cells, which was employed in the development of a reliable blocking ELISA. This work provided novel ideas and methods for the development of the blocking ELISA kits.
- 28 August 2025
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 109 (2) , 252-260
Development of Blocking ELISA Kit Based on Recombinant Monoclonal Antibody for the Serological Diagnosis of Peste Des Petits Ruminants Virus
Background: Peste des petits ruminants (PPR) is a highly contagious and economically devastating disease affecting sheep and goats. The performance and cost of serological diagnostic kits remain a major challenge for PPR eradication. Objective: The nucleocapsid (N) protein of PPR virus and its monoclonal antibody (mAb) were engineered for development of a blocking ELISA. Methods: The N protein was truncated and expressed by the eukaryotic expression system. The mAb 65A8 was recovered, followed by sequencing and cloning of its variable regions into expression vector. The recombinant mAb was expressed in 293F cells. Key characteristics of the recombinant mAb were evaluated. A blocking ELISA was developed and validated. Comparison between the blocking ELISA and a commercial blocking ELISA kit was performed. Results: The truncated N protein exhibited a higher yield compared to the full-length N protein. Recombinant mAb 65A8 demonstrated the same blocking efficacy as that of ascites-derived mAb. The yield of recombinant mAb reached 5.3 mg/100 mL. The affinity constant of recombinant mAb 65A8 was comparable to that of the ascites-derived 65A8 (3.48 × 109 L/mol versus 6.76 × 109 L/mol). Based on the truncated N and recombinant mAb, a blocking ELISA was established. The detection limit of blocking ELISA was 1:128 and 1:32 based on strong positive serum and weak positive serum, respectively. Inter- and intra-assay coefficients of variation were <10%, indicating robust reproducibility. The blocking ELISA kit showed high coincidence with the commercial ELISA kit recommended by the World Organization for Animal Health reference laboratory. Conclusions: This study successfully developed a reliable and cost-effective blocking ELISA by protein engineering of the antigen and mAb. Highlights: The mAb of PPR Virus was recombinantly expressed in 239F cells, which was employed in the development of a reliable blocking ELISA. This work provided novel ideas and methods for the development of the blocking ELISA kits.
- 20 May 2022
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 105 (5) , 1428-1436
Development of a Blocking ELISA Kit for Detection of ASFV Antibody Based on a Monoclonal Antibody Against Full-Length p72
African swine fever virus (ASFV) is the etiologic agent of African swine fever (ASF), a disease of highly contagious and significant threat to pork production. At present, the sensitive detection methods are the keys to the disease control. Full-length p72 is produced by a eukaryotic system, and its monoclonal antibody (mAb) 34C10 is subsequently recovered. A blocking ELISA kit for detection of ASFV antibody is developed based on p72 trimers and 34C10. Full-length p72 is expressed and is used as an immunogen to prepare a panel of monoclonal antibodies. The mAb 34C10 is verified by immunofluorescence and tested by ELISAs with positive serums. The constant affinity of 34C10 is then confirmed. A blocking ELISA kit is further developed and is compared with two commercial kits. The mAb 34C10 is specifically bound to p72 protein, and it exhibits a blocking effect to positive serum. The immunofluorescence assay experiment shows that 34C10 could bind to p72 expressed by baculoviruses, and the binding affinity of 34C10 is found to be as high as 1.85 × 1011 L/mol. The blocking ELISA kit shows high coincidence with a commercial ELISA kit. The sensitivity between these two kits is 97.6% (95%, CI: 90.65–99.58), and the specificity between them is 100% (95%, CI: 98.34–100). The blocking ELISA developed in this study may have great potential for diagnosis of ASF. The structure of the antigen p72 is found to be a key factor for the performance of the kit. For the first time, the eukaryotic expressed full-length p72 protein is used to recover the monoclonal antibody, and it is coated as antigen during the development of the blocking ELISA kit. This study sheds new light on the development of the blocking ELISA kits, especially for the development of a diagnostic kit for the contagious virus with bio-safety problems.
- 20 May 2022
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 105 (5) , 1428-1436
Development of a Blocking ELISA Kit for Detection of ASFV Antibody Based on a Monoclonal Antibody Against Full-Length p72
African swine fever virus (ASFV) is the etiologic agent of African swine fever (ASF), a disease of highly contagious and significant threat to pork production. At present, the sensitive detection methods are the keys to the disease control. Full-length p72 is produced by a eukaryotic system, and its monoclonal antibody (mAb) 34C10 is subsequently recovered. A blocking ELISA kit for detection of ASFV antibody is developed based on p72 trimers and 34C10. Full-length p72 is expressed and is used as an immunogen to prepare a panel of monoclonal antibodies. The mAb 34C10 is verified by immunofluorescence and tested by ELISAs with positive serums. The constant affinity of 34C10 is then confirmed. A blocking ELISA kit is further developed and is compared with two commercial kits. The mAb 34C10 is specifically bound to p72 protein, and it exhibits a blocking effect to positive serum. The immunofluorescence assay experiment shows that 34C10 could bind to p72 expressed by baculoviruses, and the binding affinity of 34C10 is found to be as high as 1.85 × 1011 L/mol. The blocking ELISA kit shows high coincidence with a commercial ELISA kit. The sensitivity between these two kits is 97.6% (95%, CI: 90.65–99.58), and the specificity between them is 100% (95%, CI: 98.34–100). The blocking ELISA developed in this study may have great potential for diagnosis of ASF. The structure of the antigen p72 is found to be a key factor for the performance of the kit. For the first time, the eukaryotic expressed full-length p72 protein is used to recover the monoclonal antibody, and it is coated as antigen during the development of the blocking ELISA kit. This study sheds new light on the development of the blocking ELISA kits, especially for the development of a diagnostic kit for the contagious virus with bio-safety problems.